The FDA has moved from saying that risk-based monitoring for clinical trials is “an important tool” to recommending “sponsors use a risk-based approach to develop their monitoring plans and to revise their monitoring plans, if needed, as the clinical investigation proceeds.” The change is reflected in the agency’s final guidance on a risk-based approach to monitoring clinical... Read More